Shares of OncoCyte Corp (NYSEAMERICAN:OCX) gapped down prior to trading on Thursday . The stock had previously closed at $4.80, but opened at $5.20. OncoCyte shares last traded at $4.98, with a volume of 9640 shares changing hands.
Several analysts recently issued reports on the company. Lake Street Capital upped their target price on OncoCyte from $4.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday. Janney Montgomery Scott upgraded OncoCyte from a “neutral” rating to a “buy” rating in a report on Tuesday. Zacks Investment Research lowered OncoCyte from a “buy” rating to a “hold” rating in a report on Saturday, January 26th. Finally, assumed coverage on OncoCyte in a report on Monday, October 29th. They set a “positive” rating on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $5.33.
OncoCyte (NYSEAMERICAN:OCX) last announced its quarterly earnings results on Tuesday, November 13th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02.
About OncoCyte (NYSEAMERICAN:OCX)
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.
Featured Article: Coverage Ratio
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.